Trial Profile

Cemiplimab/PEG-Interferon-α Combination for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Peginterferon alfa-2a (Primary)
Indications Skin cancer; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

07 Aug 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
07 Jul 2023 Planned End Date changed from 1 Jun 2028 to 1 Jul 2028.
07 Jul 2023 Planned primary completion date changed from 1 Jun 2026 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com